GB201500875D0 - Antibodies for treatment and diagnosis - Google Patents
Antibodies for treatment and diagnosisInfo
- Publication number
- GB201500875D0 GB201500875D0 GBGB1500875.8A GB201500875A GB201500875D0 GB 201500875 D0 GB201500875 D0 GB 201500875D0 GB 201500875 A GB201500875 A GB 201500875A GB 201500875 D0 GB201500875 D0 GB 201500875D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- antibodies
- diagnosis
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1500875.8A GB201500875D0 (en) | 2015-01-19 | 2015-01-19 | Antibodies for treatment and diagnosis |
PCT/EP2016/050890 WO2016116399A1 (en) | 2015-01-19 | 2016-01-18 | Anti-fibroblast activation protein (fap) antibodies for treatment and diagnosis |
US15/544,367 US10519246B2 (en) | 2015-01-19 | 2016-01-18 | Anti-fibroblast activation protein (FAP) antibodies for treatment and diagnosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1500875.8A GB201500875D0 (en) | 2015-01-19 | 2015-01-19 | Antibodies for treatment and diagnosis |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201500875D0 true GB201500875D0 (en) | 2015-03-04 |
Family
ID=52630799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB1500875.8A Ceased GB201500875D0 (en) | 2015-01-19 | 2015-01-19 | Antibodies for treatment and diagnosis |
Country Status (3)
Country | Link |
---|---|
US (1) | US10519246B2 (en) |
GB (1) | GB201500875D0 (en) |
WO (1) | WO2016116399A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230090552A1 (en) | 2020-01-08 | 2023-03-23 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
EP4326779A1 (en) | 2021-04-23 | 2024-02-28 | Philogen S.p.A. | Anti-fibroblast activation protein antibodies |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1806365A1 (en) * | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
JP5764127B2 (en) * | 2009-08-17 | 2015-08-12 | ロシュ グリクアート アーゲー | Targeted immunoconjugate |
CA2776037A1 (en) * | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd | Anti-fibroblast activation protein antibodies and methods and uses thereof |
SG187746A1 (en) * | 2010-08-13 | 2013-03-28 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
-
2015
- 2015-01-19 GB GBGB1500875.8A patent/GB201500875D0/en not_active Ceased
-
2016
- 2016-01-18 US US15/544,367 patent/US10519246B2/en not_active Expired - Fee Related
- 2016-01-18 WO PCT/EP2016/050890 patent/WO2016116399A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US20180186891A1 (en) | 2018-07-05 |
WO2016116399A1 (en) | 2016-07-28 |
US10519246B2 (en) | 2019-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL290496A (en) | Therapeutic antibodies and their uses | |
ZA201700832B (en) | Anti-pd-l1 antibodies and diagnostic uses thereof | |
IL260678B (en) | Systems and methods for improving disease diagnosis | |
EP3377102C0 (en) | Anti-pd-1 antibodies and therapeutic uses thereof | |
GB201519858D0 (en) | Therapeutic combinations comprising anti-CD73 antibodies and uses thereof | |
EP3288455C0 (en) | Diagnostic methods | |
HK1245804A1 (en) | Anti-csf1r antibodies for treating pvns | |
GB201413357D0 (en) | Antibodies for treatment and diagnosis | |
HK1247091A1 (en) | Therapeutic antibodies and uses thereof | |
PT3101132T (en) | Anti-transthyretin human antibody | |
PL3180356T3 (en) | Human anti-fgfr4 antibody | |
IL250507A0 (en) | Anti-ck8 antibodies for use in the treatment of cancers | |
IL252904A0 (en) | Methods and agents for treating disease | |
IL247797A0 (en) | Glucometer and method for use | |
SI3200783T1 (en) | Erythromelalgia treatment | |
GB201500875D0 (en) | Antibodies for treatment and diagnosis | |
GB201510676D0 (en) | Novel diagnostic and therapeutic method | |
SG11201800356WA (en) | Biological treatment device | |
GB201401806D0 (en) | Novel methods for diagnosis and therapy | |
GB201501202D0 (en) | Novel methods for diagnosis and therapy | |
PL3334479T3 (en) | Blood treatment device | |
GB201504466D0 (en) | Diagnostic assay and treatment for preeclampsia | |
GB201502741D0 (en) | Diagnostic assay and treatment for preeclampsia | |
EP3102940A4 (en) | Anti-metalloprotease antibody for diagnosis and treatment of cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |